Novartis NVS announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet ...

Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which ...

Alphabet-founded biotech Calico Life Sciences has struck an exclusive licensing agreement with Chinese drugmaker Mabwell (SHA ...

Regeneron and Sanofi are committed to helping patients in the U.S. who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...

Sonis, S. (2000) Defining Mechanisms of Action of Interleukin-11 on the Progression of Radiation-Induced Oral Mucositis in Hamsters. Oral Oncology, 36, 373-381.

Defying Age: The Intriguing Potential of Interleukin-11 Blockers A recent study has shed light on the potential of blocking interleukin-11, a protein involved in inflammation, to extend lifespan by ...

A poster entitled “LASN01, a high affinity anti-interleukin-11 receptor antibody, blocks pathological mechanisms of thyroid eye disease linked to clinical efficacy” described how LASN01 inhibits ...

Lassen Therapeutics, a clinical stage biotech company developing first-in-class antibody therapeutics targeting interleukin-11 receptor (IL-11R, LASN0 ...

Lack of IL11 (interleukin-11) signaling in mouse model of Marfan Syndrome (mMFS) mice protects against pulmonary fibrosis, emphysema, and elastolysis. A, Representative Masson’s trichrome (MT)-stained ...